Yasuhiro Miyake1, Haruhiko Kobashi, Kazuhide Yamamoto. 1. Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. miyakeyasuhiro@hotmail.com
Abstract
PURPOSE: In patients chronically infected with hepatitis B virus, interferon has been used for the purpose of viral suppression by loss of hepatitis B e antigen (HBeAg) with or without seroconversion to antibody to HBeAg (anti-HBe). However, discussion about the effect of interferon on the development of hepatocellular carcinoma (HCC) has been controversial. METHODS: We conducted a meta-analysis of published studies. Eight studies were retrieved (1,303 patients), including two randomized controlled trials (RCTs) and six non-RCTs (553 patients received interferon treatment). RESULTS: The pooled estimate of the preventive effect of treatment was significantly in favor of interferon (risk difference -5.0%; 95% CI -9.4 to -0.5, P = 0.028). By subgroup analyses, the preventive effect of interferon treatment was shown in the Asian population (risk difference -8.5%; 95%CI -13.6 to -3.6, P = 0.0012), the population with the incidental rate of HCC >or=10% if untreated with interferon (risk difference -9.4%; 95%CI -14.2 to -4.6, P = 0.0001), and the population with the proportion of HBeAg-positive patients to the study population >or=70% (RD -6.0%; 95%CI -11.8 to -0.2, P = 0.043). However, the preventive effect of interferon was not shown in the European population, the population with a lower incidental rate of HCC if untreated with interferon, and the population with the lower proportion of HBeAg-positive patients to the study population. An evaluation using the Begg method indicated no evidence of publication bias. CONCLUSIONS: Interferon treatment is considered to restrain HCC development in patients with chronic hepatitis B virus infection, especially in HBeAg-positive Asians.
PURPOSE: In patients chronically infected with hepatitis B virus, interferon has been used for the purpose of viral suppression by loss of hepatitis B e antigen (HBeAg) with or without seroconversion to antibody to HBeAg (anti-HBe). However, discussion about the effect of interferon on the development of hepatocellular carcinoma (HCC) has been controversial. METHODS: We conducted a meta-analysis of published studies. Eight studies were retrieved (1,303 patients), including two randomized controlled trials (RCTs) and six non-RCTs (553 patients received interferon treatment). RESULTS: The pooled estimate of the preventive effect of treatment was significantly in favor of interferon (risk difference -5.0%; 95% CI -9.4 to -0.5, P = 0.028). By subgroup analyses, the preventive effect of interferon treatment was shown in the Asian population (risk difference -8.5%; 95%CI -13.6 to -3.6, P = 0.0012), the population with the incidental rate of HCC >or=10% if untreated with interferon (risk difference -9.4%; 95%CI -14.2 to -4.6, P = 0.0001), and the population with the proportion of HBeAg-positive patients to the study population >or=70% (RD -6.0%; 95%CI -11.8 to -0.2, P = 0.043). However, the preventive effect of interferon was not shown in the European population, the population with a lower incidental rate of HCC if untreated with interferon, and the population with the lower proportion of HBeAg-positive patients to the study population. An evaluation using the Begg method indicated no evidence of publication bias. CONCLUSIONS: Interferon treatment is considered to restrain HCC development in patients with chronic hepatitis B virus infection, especially in HBeAg-positive Asians.
Authors: Hajo J Flink; Bettina E Hansen; E Jenny Heathcote; S Victor Feinman; Halis Simsek; Selim Karayalcin; Tomasz Mach; Wim F Leemans; Robert A de Man; Elke Verhey; Solko W Schalm; Harry L A Janssen Journal: Am J Gastroenterol Date: 2006-10-04 Impact factor: 10.864
Authors: Seng Gee Lim; Tay Meng Ng; Nelson Kung; Zahary Krastev; Miroslava Volfova; Petr Husa; Samuel S Lee; Sing Chan; Mitchell L Shiffman; Mary Kay Washington; Amy Rigney; Jane Anderson; Elsa Mondou; Andrea Snow; Jeff Sorbel; Richard Guan; Franck Rousseau Journal: Arch Intern Med Date: 2006-01-09
Authors: T Fujisawa; H Komatsu; A Inui; T Sogo; Y Miyagawa; S Fujitsuka; I Sekine; T Kosugi; M Inui Journal: J Pediatr Gastroenterol Nutr Date: 2000-02 Impact factor: 2.839
Authors: C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray Journal: N Engl J Med Date: 1998-07-09 Impact factor: 91.245
Authors: Alberto Ferrarese; Alberto Zanetto; Martina Gambato; Ilaria Bortoluzzi; Elena Nadal; Giacomo Germani; Marco Senzolo; Patrizia Burra; Francesco Paolo Russo Journal: World J Gastroenterol Date: 2016-01-28 Impact factor: 5.742